Investor Overview

Investor Overview

Corporate Profile

ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates that activate the immune system of cancer patients to recognize and eradicate tumors. The Company’s lead product candidate, AM0010 (pegilodecakin), is being evaluated in an ongoing Phase 1/1b clinical trial as a therapy for pancreatic cancer, non-small cell lung cancer, renal cell carcinoma, colorectal carcinoma and melanoma. In addition, AM0010 is being evaluated in a Phase 3 randomized pivotal clinical trial in pancreatic cancer patients, which compares a combination of AM0010 and FOLFOX to FOLFOX alone, as a second-line therapy after tumor progression during or following a gemcitabine-containing regimen. The Company also has a number of other immuno-oncology product candidates aimed at treating a variety of cancers in combination with standard of care treatments and emerging immunotherapies. These candidates are in various stages of pre-clinical development, and include: AM0001, an anti-PD-1 checkpoint inhibitor; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, a form of recombinant human Interleukin-15 (IL-15) cytokine; and AM0012, a form of recombinant human Interleukin-12 (IL-12) cytokine.

Stock Quote

Copyright Nasdaq. Minimum 15 minutes delayed.

News Releases
April 2, 2018
ARMO BioSciences Reports FY 2017 Financial Results

First Patient Enrolled in CYPRESS 1 Trial in Non-Small Cell Lung Cancer REDWOOD CITY, Calif. , April 02, 2018 (GLOBE NEWSWIRE) --   ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology company, today announced its financial results for the fiscal year ended December 31, 2017 .

Events
More events are coming soon.